Waseem D.
- Country
- Ireland
- Department
- Medical Oncology
Research Overview
- Phase 3 Randomized Trial of Intravesical Erdafitinib Delivery System vs. Single-Agent Chemotherapy in FGFR+ Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- Phase III Randomized Trial of Intermittent vs. Continuous Androgen Deprivation Therapy with AR Pathway Inhibitors in Metastatic Hormone-Naïve Prostate Cancer
Data & Insights
Has run more than one trial at 18 of 131 partner sites.
Specializations
Urological Oncology
The investigator specializes in treating complex urological cancers, with particular expertise in bladder cancer and prostate cancer management.
- FGFR-positive bladder cancer interventions
- Non-muscle invasive bladder cancer treatment
- Metastatic hormone-naïve prostate cancer therapy
Their research focuses on targeted therapeutic approaches for patients with specific genetic alterations in bladder cancer.
Precision Medicine
The investigator concentrates on developing personalized treatment strategies based on genetic markers and specific patient characteristics.
- FGFR gene alteration analysis
- Targeted intravesical therapies
- Hormone therapy optimization
Their work involves evaluating novel therapeutic approaches for genetically defined patient populations.
Therapeutic Innovation
The investigator explores advanced treatment modalities in urological oncology, particularly focusing on hormone therapy strategies.
- Androgen blockade therapy protocols
- Quality of life optimization
- Novel therapeutic combinations
Their research includes investigating innovative approaches to maximize treatment effectiveness while maintaining patient wellbeing.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.